Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position

Core Viewpoint - Poxel reported a consolidated revenue of €5 million for the fiscal year ended December 31, 2025, reflecting a decrease from €6.6 million in 2024, primarily due to the absence of a milestone payment received in the previous year [1] Financial Performance - Cash and cash equivalents as of December 31, 2025, amounted to €0.9 million, an increase from €0.6 million as of September 30, 2025 [1] - Gross sales of TWYMEEG® in Japan increased by 15% in Q4 2025 compared to Q3 2025, and by 40% compared to Q4 2024 [1] - Poxel received ¥873 million in royalties from Sumitomo Pharma, with a retroactive adjustment leading to an additional ¥88 million for the second and third quarters of 2025 [1] Revenue Breakdown - The royalty rate for TWYMEEG® was 10% in Q1 and Q4 2025, and 8% in Q2 and Q3 2025, with total royalties for the year amounting to €4.5 million [1] - The breakdown of quarterly revenues for 2025 was as follows: Q1 - €1.06 million, Q2 - €1.26 million, Q3 - €1.29 million, Q4 - €1.40 million [1] Strategic Developments - Poxel's continuation plan was approved by the Lyon Commercial Court on January 22, 2026, concluding the judicial reorganization proceedings and allowing the company to implement its recovery plan [1] - The company anticipates double-digit royalty growth on TWYMEEG® sales in 2026 [1]